Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Subject is a male or a post-menopausal female.~* Primary insomnia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised for at least 3 months and a history of daytime complaint(s) associated with disturbed sleep.~* Subjective sleep latency greater than or equal to 45 minutes and a subjective total sleep time less than or equal to 6.5 hours per night for at least 3 nights during the week of the lead-in period.~* Habitual bedtime is between 8:30 PM and 12:00 AM.~* Body mass index between 18 and 34, inclusive.~Exclusion Criteria~* Known hypersensitivity to ramelteon or related compounds, including melatonin.~* Previously participated in a study involving ramelteon.~* Participated in any other investigational study, and/or took any investigational drug within 30 days or five half-lives prior to the first day of single-blind study medication, whichever is longer.~* Sleep schedule changes required by employment (eg, shift worker) within three months prior to the first day of single-blind study medication, or has flown across greater than three time zones within seven days prior to screening.~* Participated in a weight loss program or substantially altered exercise routine within 30 days prior to the first day of single blind study medication.~* Has ever had a history of seizures, sleep apnea, chronic obstructive pulmonary disease, restless leg syndrome, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.~* History of psychiatric disorder within the past 12 months.~* History of drug addiction or drug abuse within the past 12 months.~* History of alcohol abuse within the past 12 months, as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised and/or regularly consumes 4 or more alcoholic drinks per day.~* Current significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic or metabolic disease, unless currently controlled and stable with protocol-allowed medication.~* Uses tobacco products during nightly awakenings.~* Any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.~* Positive hepatitis panel.~* Any additional condition(s) that in the Investigator's opinion would:~  * affect sleep-wake function~ * prohibit the subject from completing the study~ * not be in the best interest of the subject.~* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication, including:~  * Anxiolytics~ * Hypnotics~ * Antidepressants~ * Anticonvulsants~ * Sedating H1 antihistamines~ * Systemic steroids~ * Respiratory stimulants~ * Decongestants~ * Over-the-counter and prescription stimulants~ * Over-the-counter and prescription diet aids~ * Central nervous system active drugs~ * Narcotic analgesics~ * All beta blockers~ * Melatonin~ * St. John's Wort~ * Kava-kava~ * Gingko biloba

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ramelteon 4 mg QD (Type: EXPERIMENTAL): None
- Ramelteon 8 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete